Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday’s session after the company reported worse-than-expected first-quarter revenue. NetEase reported…
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.